Welcome to KodaKoda's Weekly Immunology News, your go-to source for the latest in immunology and microbiology research. I'm so glad you're joining me today because we have a packed episode full of fascinating science, from deadly tick-borne viruses spreading across Europe to how your skin bacteria might be keeping you young, and some really exciting work on cancer immunotherapy and gut microbiome ecology. Let's dive right in.
We're starting with a story that's been on the radar of public health officials in Europe, and it's one that deserves a lot more attention. Published on August 27th 2026 in the journal Science, Richard Stone from Pristina in Kosovo has a piece titled Deadly tick-borne virus gains ground in Europe. The abstract is short but pointed. Kosovo's surveillance experience could help other countries prepare before human cases appear. Now that might seem brief for a scientific publication, but the message is actually really important. Kosovo has been on the front lines of tracking this tick-borne virus, and the idea here is that countries across Europe can learn from how Kosovo has set up its surveillance infrastructure. Before you even see a single human case, you want systems in place to detect and respond. This is classic preparedness epidemiology, and in the context of a changing climate that's expanding tick habitats further north and west across Europe, this kind of early warning science is genuinely critical. Something to keep an eye on.
Right alongside that in the same August 27th issue of Science, we have another piece with a headline that might catch you off guard. It's called Beyond Wrinkles, and it comes from Sasan Jalili at the Jackson Laboratory for Genomic Medicine in Farmington Connecticut. The abstract poses the question simply and beautifully. Can the skin microbiome shape healthy aging? Now this is a topic that's starting to get real scientific traction. We've known for a while that the gut microbiome, the community of microorganisms living in your digestive system, plays a massive role in health and disease. But the skin microbiome, the bacteria fungi and other microbes living on the surface of your body, is a whole other frontier. The suggestion here is that it's not just about cosmetics or surface-level health, but that what's living on your skin might actually influence how you age from the inside out. We're talking about immune signaling, inflammation, metabolic function. Really exciting territory, and we'll definitely be watching as more research comes out on this.
Now let's get into some of the heavier science because this next paper is genuinely important for the millions of people worldwide who live with inflammatory bowel disease. Published in Science on August 27th 2026, Jiyi Pang from the Walter and Eliza Hall Institute of Medical Research in Parkville Victoria Australia leads a study titled A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease.
So what does that title actually mean? Let me break it down. Inflammatory bowel disease, which most people know as IBD, is a chronic condition that includes diseases like Crohn's disease and ulcerative colitis. It's caused by a combination of factors including altered cytokine signaling, which is the way immune cells communicate with each other, maladaptive immunity where the immune system starts attacking the body's own tissues, dysbiosis which is an imbalance in the gut microbial community, and intestinal barrier dysfunction where the lining of the gut becomes damaged and leaky.
Now current therapies for IBD try to correct these imbalances to bring patients into remission. But here's the frustrating reality that anyone with IBD knows all too well. Most patients ultimately relapse, which means something deeper is going on that the current treatments aren't addressing.
What Pang and colleagues found is really striking. They identified aberrant, meaning abnormal or dysregulated, epithelial cell death signaling as an underlying feature of IBD. And crucially, this is present even in patients who are in remission and on advanced therapy. So the disease is still quietly active at the cellular level even when someone feels better.
Mechanistically, and this is the really fascinating part, they found that early inflammation was pushing the epithelial cells, which are the cells that line the gut, into a transcriptional state that resembles M1 macrophages. Macrophages are a type of immune cell, and M1 macrophages are the pro-inflammatory kind. So these gut lining cells were essentially being reprogrammed to behave more like angry immune cells rather than the protective barrier cells they're supposed to be.
This shift promoted a specific type of cell death signaling called RIPK1-independent necroptotic signaling. Necroptosis is a form of programmed cell death that's distinct from apoptosis, which is the clean, controlled form of cell death that happens normally. Necroptosis is messier and more inflammatory. And this necroptotic signaling then triggered something called inducible nitric oxide synthase-assisted mitochondrial apoptosis of absorptive epithelial cells, along with PUMA-mediated intestinal stem cell death.
In plain language, the gut's absorptive cells and the stem cells that replenish them were being killed off through this cascade, which would obviously compromise the gut barrier and perpetuate the disease. The key takeaway is that this aberrant cell death signaling is a hallmark of IBD that appears early in mucosal lesion development, persists even with current treatments, and importantly predicts clinical relapse. This could open the door to a whole new class of IBD therapies targeting cell death pathways rather than just inflammation. Huge implications.
Moving into microbiology now, and this one is a real deep dive into host-pathogen interaction. Published in the Proceedings of the National Academy of Sciences for September 2026, Mary Dickinson from the Department of Molecular Genetics and Microbiology at Duke University Medical Center has a paper titled RNF213-dependent lytic destruction of Chlamydia-containing vacuoles activates host cell death pathways.
So let's set the scene. When the body detects an infection, one of its key weapons is interferon, specifically a cytokine called gamma-interferon. This molecule promotes what's called cell-autonomous immunity, meaning individual cells can defend themselves. It does this by turning on hundreds of interferon-stimulated genes, or ISGs.
One of these ISGs is a protein called RNF213, which is a ubiquitin E3 ligase. Without getting too deep into the biochemistry, ubiquitin ligases are enzymes that tag proteins for degradation or other fates. RNF213 is known to protect host cells from a wide range of intracellular pathogens, and one of those pathogens is Chlamydia.
Now Chlamydia trachomatis, the human pathogen responsible for the most common bacterial sexually transmitted infection worldwide, normally has a neat trick to avoid RNF213. It uses a secreted virulence effector protein called GarD to evade RNF213-mediated killing. But without GarD, RNF213 gets recruited to the vacuolar compartment where Chlamydia replicates inside the cell. This compartment is called the inclusion. Once there, RNF213 tags components of the inclusion membrane with ubiquitin, a process called ubiquitylation.
Now typically when pathogens get tagged with ubiquitin inside cells, the cell uses a process called xenophagy, which is basically a specialized form of autophagy or cellular self-digestion, to destroy the pathogen-containing vacuole. Dickinson and her team found that xenophagy can indeed degrade inclusions, but here's the twist: xenophagy is actually dispensable for RNF213-dependent killing of Chlamydia. There's another mechanism at play.
What they discovered is that RNF213 targeting can actually cause the inclusion to lyse, meaning it ruptures. This releases the bacteria directly into the host cell's cytosol, which is the fluid interior of the cell. And this triggers two distinct host cell death pathways. The first is a rapid cell death that morphologically looks like apoptosis, but is actually independent of the classical apoptosis effectors caspase-3 and caspase-7. Instead it requires a secreted Chlamydia protease called CPAF. The second is a slower cell death that doesn't require CPAF but instead depends on cytosolic pattern-recognition receptors called RIG-I and STING, which are part of the innate immune sensing machinery.
So RNF213-driven lysis of pathogen-containing vacuoles is a previously unrecognized defense mechanism that triggers a host-pathogen battle over cytosolic immune activation. Really elegant work revealing layers of immune defense that we didn't know existed.
Let's talk gut microbiome science now because this next paper from Cell Reports, published August 27th 2026, takes a really sophisticated approach to understanding how the microbial community in your gut is organized and how that relates to disease. Yuzheng Gu from the State Key Laboratory of Genome and Multi-omics Technologies at BGI Research in Shenzhen China leads a study called Complete genome-derived metabolic interactions reveal the impact of gut ecology on human health.
The core problem they're addressing is this. We know that metabolic interactions between microbes govern how the gut microbiome is assembled and maintained. But our understanding of these interactions has been really limited because most genomic data from gut microbes comes from incomplete or fragmented genome sequences, which miss critical information. Gu and colleagues leveraged 1150 complete genomes to build genome-scale metabolic models, and they showed that using incomplete draft assemblies introduces systematic errors and leaves out critical transport functions.
What they found is that metabolic competition and complementarity between microbes are not random. They're shaped by genomic traits and niche specialization. Think of it like different species in an ecosystem each occupying a specific role. They stratified gut microbial strains into four ecological groups. Active players, resource predators, resource utilizers, and resource contributors, each with distinct signatures in terms of what metabolites they exchange, how they compete, and what secondary metabolites they produce.
In the context of inflammatory bowel disease, they found that these groups showed subtype-specific temporal instability, and importantly, group-specific dysbiosis predicted clinical phenotypes better than whole-community profiles. They also found that keystone features from integrated metabolic interaction and co-occurrence networks improved disease classification. This work fundamentally connects genomic completeness with microbial ecological organization and gives us a much richer framework for understanding how metabolic interactions in the gut contribute to disease.
Now here's a paper that sits squarely at the intersection of cancer biology and immunology, and it has real clinical implications. Also in Cell Reports on August 27th 2026, Thomas Fabre from Pfizer's Inflammation and Immunology Research Unit in Cambridge Massachusetts published Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity.
Immune checkpoint inhibitors have been transformative for cancer treatment. These are drugs that essentially take the brakes off the immune system so it can recognize and attack tumors. PD-1 inhibition is one of the most successful of these approaches. But resistance to checkpoint inhibitors remains a huge problem in oncology.
The focus of this paper is on type 2 cytokines, specifically IL-4, IL-13, and thymic stromal lymphopoietin or TSLP. These are signaling molecules associated with allergic and anti-parasitic immune responses, and they've been implicated in suppressing anti-tumor immunity. The researchers wanted to know whether blocking all three together could enhance anti-tumor responses, both alone and in combination with PD-1 inhibition.
They found that IL-4 specifically impaired T cell-mediated tumor control and reduced the expression of immune-stimulatory molecules by monocyte-derived dendritic cells in laboratory conditions. In mouse tumor models, combined blockade of IL-4, IL-13, TSLP, and PD-1 improved tumor growth inhibition and was associated with reprogramming of T cells, monocytes, and dendritic cells toward anti-tumor phenotypes. And across multiple human cancer datasets, transcriptional signatures associated with IL-4 and IL-13 and TSLP activity correlated with poorer survival.
This work identifies type 2 cytokine signaling as a meaningful suppressive pathway in anti-tumor immunity and supports the idea of targeting it therapeutically to boost checkpoint inhibitor efficacy. Potentially very important for patients who don't respond to current immunotherapy.
Next up is a really innovative paper about radiotherapy and the immune system. Published in Science Advances on August 28th 2026, Chong Li from Fudan University Shanghai Cancer Center presents Carbon ion irradiation at a clinically used dose rewires super-enhancers to drive necroptosis and systemic immunity.
So conventional radiotherapy typically uses X-rays at doses around 2 Gy per fraction. At this dose, X-rays mostly cause apoptosis, which is the controlled form of cell death. More robust immunogenic cell death, the kind that really activates the immune system, is usually associated with higher doses. But here's the thing about carbon ion radiotherapy. Even at the same low physical dose of 2 Gy, carbon ions, which are heavy charged particles, have a fundamentally different biological effect compared to X-rays because they have high linear energy transfer or high LET.
What Li and colleagues found is that 2 Gy of carbon ions redirects cell death away from apoptosis toward MLKL-dependent necroptosis and triggers an NF-kappa-B-driven inflammatory cascade involving cytokines and chemokines including IL-1A, IL-1B, CXCL1, CXCL2, and CXCL3. This actually surpassed the immunogenicity of 8 Gy X-rays despite causing less direct tumor cell killing.
The mechanism involves something called super-enhancer remodeling. Super-enhancers are large clusters of regulatory DNA elements that drive high-level expression of key genes. Clustered DNA damage from carbon ions acts as an epigenetic switch, suppressing the classical apoptosis pathway while licensing inflammatory necroptosis. When the researchers pharmacologically inhibited MLKL, which is a key effector in the necroptosis pathway, these immune responses were abolished.
In vivo, 2 Gy carbon ion radiotherapy drove an abscopal response, meaning it had immune effects beyond the directly irradiated tumor site, and was associated with increased CD8+ T cell infiltration and function. This provides a strong mechanistic rationale for integrating carbon ion radiotherapy into next-generation radio-immunotherapy combinations.
Let's talk about a serious side effect of cancer immunotherapy next. Published also in Science Advances on August 28th 2026, Carly Tymm from the Columbia Center for Translational Immunology at Columbia University Medical Center in New York presents Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.
Immune checkpoint inhibitor myocarditis is a rare but frequently fatal inflammatory condition affecting the heart that can occur as a side effect of cancer immunotherapy. When it happens, it's devastating, and understanding its mechanism is crucial for figuring out how to treat it without undermining the anti-tumor effects of the therapy.
Using integrated spatial and single-cell analyses in a pharmacological murine model, Tymm and colleagues identified regional infiltration of Ly6C-positive monocytes and PD-1-positive CD8+ T cells in the heart. These immune cells organized into fibroblast-rich immune structures, which the authors call tertiary T cell niches or TTCNs. These structures function as hubs for T cell activation and share features with tertiary lymphoid structures, which are organized immune aggregates that can form in non-lymphoid tissues during chronic inflammation.
A gene signature derived from TTCNs was strongly enriched in cardiac tissue from patients with ICI myocarditis, validating the relevance of this finding in human disease. Complementary T cell receptor analyses revealed clonal expansion of cardiac T cells following ICI treatment, which is a hallmark of a targeted adaptive immune response. The researchers also identified TTCN-associated cytokines and structural proteins as candidate therapeutic targets that could potentially reduce myocardial inflammation while preserving tumor control. This is genuinely important work for making cancer immunotherapy safer.
Now here's something completely different and absolutely fascinating. Published in Science Advances on August 28th 2026, Jeric Da-Anoy from the Department of Biology at Boston University presents Algae-specific immune modulation influences responses to heat and pathogen challenge in a symbiotic coral.
Corals have a symbiotic relationship with photosynthetic algae called dinoflagellates that live inside their cells. The type of algae a coral hosts has major implications for its resilience and health. This study looked specifically at the tropical coral Pocillopora acuta and compared corals hosting two different symbiont types. Those hosting Durusdinium and those hosting Cladocopium.
Corals hosting Durusdinium are known to be more thermotolerant, meaning they handle heat stress better, but there's been an observation that this association can also lead to more tissue loss under stress. The question was why.
Da-Anoy and colleagues found that Durusdinium-hosting corals had distinct transcriptomic profiles, higher immune-related gene expression, and elevated baseline levels of the immunity transcription factor nuclear factor kappa B compared to Cladocopium-hosting corals. Under heat challenge, Durusdinium-hosting corals showed tissue loss, oxidative stress, and immune and microbial dysregulation. Meanwhile Cladocopium-hosting corals were more susceptible to bleaching and metabolic dysregulation.
When infected with the bacterium Vibrio coralliilyticus, Durusdinium-hosting corals suffered high tissue loss, while Cladocopium-hosting corals did not. This suggests a genuine immune trade-off. The thermotolerance conferred by Durusdinium comes with an immune configuration that predisposes corals to tissue damage under stress, especially pathogen challenge. With climate change driving ocean warming, understanding these trade-offs in coral immune ecology is more important than ever.
Next is a really elegant paper about plant immunity and the microbiome. Published in Science Advances on August 28th 2026, Xuemei Wang from the State Key Laboratory of Seed Innovation at the Institute of Genetics and Developmental Biology at the Chinese Academy of Sciences in Beijing presents A vitamin B3-driven root bacterial metabolite primes systemic immunity in Arabidopsis.
So plants, like animals, have microbiomes. The community of microorganisms living around and on plant roots is called the rhizosphere microbiome, and it can influence plant health in profound ways. This study found that vitamin B3, also known as niacin, secreted by plant roots shapes the assembly of a functionally specialized root microbiota, which in turn metabolizes vitamin B3 into an immune-active signal.
Specifically, vitamin B3 secretion selectively increases the abundance of root-associated bacteria that carry a conserved biosynthetic gene cluster called the nic BGC, which enables the conversion of vitamin B3 into a compound called 6-hydroxynicotinate or 6-OHNA. This is a previously uncharacterized microbial metabolite in the context of plant-microbe interactions.
Microbially produced 6-OHNA is transported from roots to shoots, where it primes systemic immune responses in a salicylic acid-dependent manner. When the microbial nic BGC was disrupted, immune priming was abolished. When plant roots exuded more vitamin B3, disease resistance was enhanced. This reveals a sophisticated metabolic dialogue between plants and their microbiota, connecting host nutrient secretion to microbial functional specialization and the activation of systemic plant immunity. Beautiful biology.
Now let's move to some really clinically relevant work in reproductive and perinatal medicine. Published in Science Translational Medicine on August 26th 2026, Samantha Ottinger from the Department of Molecular Virology and Microbiology at Baylor College of Medicine in Houston Texas presents Urogenital immune signatures are associated with birth outcomes after maternal urinary tract infection.
Preterm birth is the leading cause of infant mortality globally, responsible for more than one million neonatal deaths every year. Maternal urinary tract infection during pregnancy is a known risk factor for preterm birth, but the biological mechanisms mediating this connection have not been well understood.
Ottinger and colleagues established a murine maternal UTI model using uropathogenic Escherichia coli, or UPEC, and found that infection initiated preterm labor and birth in about half of the mouse mothers. Even though bacterial burdens were similar across all infected animals, those that experienced preterm birth showed excessive bladder inflammation, elevated cytokines in the placenta and decidua, higher proportions of male fetuses, and lower levels of interleukin-10 in maternal serum compared to mothers that did not go into labor.
Interleukin-10, or IL-10, is an anti-inflammatory cytokine. When the researchers provided exogenous IL-10 or sequestered T cells in lymph nodes, they reduced placental TH17 cells, which are a pro-inflammatory subset of T helper cells, and this abrogated preterm birth.
In a human pregnancy cohort, urinary cytokines correlated with birth outcomes and urine culture status. This analysis yielded an exploratory noninvasive system for evaluating preterm birth risk that implicates T cell-related cytokines including IL-10, IL-15, GM-CSF, and RANTES. Really important work that connects immunological and microbial factors to one of the most significant clinical problems in obstetrics.
From preterm birth to vaccine side effects, this next paper addresses something that pretty much everyone who has received an mRNA vaccine has experienced. Also in Science Translational Medicine on August 26th 2026, Natacha Madelon from the Centre for Vaccinology at the University of Geneva in Switzerland presents Baseline interferon signaling in monocytes and antibody-mediated innate activation are associated with reactogenicity to mRNA vaccines.
Reactogenicity refers to the local and systemic symptoms that follow vaccination. Things like soreness at the injection site, fatigue, fever, chills. These are common with mRNA vaccines, but there's huge individual variability. Some people feel fine the next day. Others are bedridden. Why?
Through longitudinal immune profiling of vaccinated individuals and mechanistic studies in mice, Madelon and colleagues identified key immunological determinants. Systemic adverse events were associated with stronger interferon and pro-inflammatory responses after the second dose of a COVID-19 mRNA vaccine. And importantly, these responses were also correlated with the magnitude of antigen-specific adaptive immune responses, suggesting that people who react more are also building stronger immunity.
This heightened inflammation occurred within 24 hours of vaccination, originated primarily from the injection site, and involved enhanced recruitment and activation of myeloid cells, particularly monocytes. Two mechanisms contributed. First, early interferon production by muscle T cells that were generated after the first dose. Second, Fcγ receptor-dependent chemokine induction by vaccine antigen-specific antibodies. So your pre-existing antibodies from the first dose are actually amplifying the reaction to the second dose.
Beyond this, the baseline immune state also mattered. Individuals with a preexisting interferon-stimulated gene signature in monocytes, detectable at both transcriptomic and epigenetic levels, were more prone to systemic symptoms. This provides a really comprehensive framework for understanding vaccine reactogenicity and for potentially designing less reactogenic vaccines in the future.
Now here's an important paper for colorectal cancer research. Published in Science Translational Medicine on August 26th 2026, Songtao Ji from the State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers at Xijing Hospital at the Fourth Military Medical University in Xi'an China presents LTBP4 deficiency induces MRC1-positive CD44-positive macrophages to drive cancer progression in preclinical colorectal cancer models.
The tumor microenvironment, which is the ecosystem of cells and molecules surrounding a tumor, is crucial for cancer progression. This study identified a protein called LTBP4, which stands for latent transforming growth factor-beta binding protein 4, as a key regulator of tumor-associated macrophages in colorectal cancer.
When LTBP4 is deficient in colorectal cancer, it reprograms tumor-associated macrophages, or TAMs, and induces a distinct subset that promotes tumor progression by coordinating immune evasion and extracellular matrix remodeling. In patients, LTBP4 deficiency correlated with cancer progression and poor survival. In immunocompetent mice, knockout of Ltbp4 markedly promoted tumor growth and metastasis, but this effect was attenuated in immunodeficient hosts, establishing that the immune system is essential in mediating these effects.
Single-cell RNA sequencing revealed that LTBP4 deficiency induced a specific macrophage subset characterized by expression of mannose receptor C-type 1, or MRC1, and CD44, and this was correlated with reduced CD8+ T cell infiltration in tumors.
Mechanistically, LTBP4 deficiency increased active TGFbeta1 levels, which acted in a paracrine manner to upregulate MRC1 in TAMs, while autocrine signaling induced an enzyme called HAS2 that produces hyaluronan, increasing CD44. CD44 signaling in TAMs then upregulated matrix metalloproteinases for collagen degradation, while MRC1 mediated collagen internalization, cooperatively remodeling the extracellular matrix to facilitate tumor invasion. These MRC1-positive CD44-positive TAMs further suppressed CD8+ T cell function by diminishing the CXCL16-CXCR6 signaling axis.
Therapeutically, depleting these macrophages enhanced the efficacy of PD-1 blockade in LTBP4-deficient tumors. This positions LTBP4 as a key modulator of tumor progression and reveals a potentially actionable therapeutic strategy.
In the realm of neuroimmunology, a fascinating discovery was published in Science Translational Medicine on August 26th 2026. Hoi Kiu Wong from the Institute of Clinical Neuroimmunology at Ludwig-Maximilians-Universität München in Munich Germany presents Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models.
Neuromyelitis optica spectrum disorder, or NMOSD, is a severe autoimmune disease of the central nervous system. The identification of autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein, or MOG, has been essential in distinguishing NMOSD and MOG antibody-associated disease from classical multiple sclerosis. But for some patients with symptoms overlapping these conditions, the target of the autoimmune response has been unknown.
Wong and colleagues identified MLC1, the modulator of VRAC current 1, as a new autoantigen. MLC1 is a membrane protein with extracellular epitopes enriched at astrocytic end feet, which are the projections of astrocytes that contact blood vessels in the brain. Using a cell-based assay, they identified four MLC1 immunoglobulin G-positive patients among 297 patients with inflammatory autoimmune diseases of the central nervous system. All four were negative for AQP4 and MOG antibodies and had overlapping but atypical clinical features of both MS and NMOSD. Treatment with a monoclonal MLC1 antibody induced astrocytopathy in mouse cerebellar slice cultures and in a rat encephalitis model. This identifies MLC1 antibodies as markers of a distinct patient subset with pathogenic relevance, potentially opening the door to better diagnosis and treatment for these patients.
Our next paper brings macrophage biology into the world of obesity and weight loss. Published in Science Translational Medicine on August 26th 2026, Takuro Miyazaki from Showa Medical University Graduate School of Pharmacy in Tokyo presents Aberrant alternative splicing memorized in adipose tissue macrophages impedes efferocytosis during postobesity weight loss.
We know that obesity leaves an epigenetic memory in adipose tissue macrophages, which are the immune cells residing in fat tissue, and that proinflammatory traits can persist even after weight loss. This study digs into a specific molecular mechanism behind this memory.
Miyazaki and colleagues found that aberrant messenger RNA splicing, caused by dysfunction of the CWC22 exon junction complex, limits efferocytosis, which is the process by which macrophages engulf and clear dead cells, in macrophages during postobesity weight loss. Using multiomics and gene-targeting approaches, they found that 51.9% of obesity-induced differentially spliced genes in adipose tissue macrophages remained altered after weight loss. One-quarter of these persistent changes depended on CWC22.
A specific splicing event involving a gene called Scarb1 caused exon skipping that increased the expression of a receptor called SR-BII, promoting the formation of heterodimers between SR-BI and SR-BII that were then degraded. This reduced surface SR-BI in macrophages, suppressed efferocytosis and inosine release from dead cells, and impaired inosine-induced lipolysis in white adipose tissue.
Restoring Scarb1 splicing with an antisense oligonucleotide rescued SR-BI expression, efferocytosis, inosine availability, and fat loss in Cwc22-deficient mice. In human adipose tissue, CWC22 showed normal nuclear localization in lean individuals but markedly diminished nuclear localization in obese individuals. This reveals that aberrant alternative splicing in macrophages underlies resistance to postobesity weight loss and suggests that splicing-targeted therapies could potentially counteract obesity memory. Really novel and clinically meaningful.
From weight loss biology to cancer immunotherapy targets, we have another Cell Reports paper, this one published August 26th 2026. Brian Mooney from the BC Cancer Research Institute in Vancouver Canada presents Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma.
Osteosarcoma is the most common human primary bone cancer, primarily affecting children and young adults. For patients with localized disease, the survival rate is around 65%, but for metastatic disease that drops to roughly 20%, and recurrent disease remains largely incurable. There is a desperate need for new therapeutic strategies.
Mooney and colleagues analyzed the surfaceomes and global proteomes of 22 unique osteosarcoma patient-derived xenografts using mass spectrometry to identify surface proteins that could be targeted by immunotherapy. Both methods identified known osteosarcoma-associated surface candidates including LRRC15, MMP14, MRC2, and CADM1, as well as several poorly characterized targets including ROR2 and TMEM119. Both ROR2 and TMEM119 displayed robust expression in osteosarcoma tissues but limited or no expression in normal pediatric tissues, making them attractive targets. Loss of both targets also reduced migration of osteosarcoma cells. This study provides a valuable resource of surface proteins as potential immunotherapeutic targets in osteosarcoma.
We're going to close out our main segment with a paper that unfortunately was provided without its complete abstract, but the title and institution give us enough to flag it as important. Published in the Proceedings of the National Academy of Sciences for September 2026, Jing Wang from a State Key Laboratory, with the title Amino acid homeostasis by CORVET/HOPS a metabolic and stress resilience checkpoint for T cells. CORVET and HOPS are vesicle-tethering complexes involved in endosomal and lysosomal function, and amino acid sensing through these pathways is critical for T cell activation and survival. We'll look forward to covering the full findings when the complete abstract is available.
Now before we wrap up, I want to briefly touch on a few articles that came through without abstracts this week, but that are too significant to skip over.
First, Roland Muhindo Muyisa from the Catholic University of Graben in Butembo in the Democratic Republic of the Congo has a piece in Nature Medicine dated August 25th 2026, titled Beyond Ebola armed conflict and humanitarian funding cuts threaten control of malaria TB and HIV in eastern DRC. The title says it all. This is an urgent public health call to attention about how the crises of armed conflict and funding cuts are compounding disease burden in one of the most vulnerable regions in the world.
In Nature, also from August 25th 2026, there's a piece titled Asthma in some boys stops at puberty mouse results hint at why. This is a classic observation in clinical medicine that asthma in boys often improves around puberty while it tends to persist or worsen in girls, and new mouse research seems to be shedding some mechanistic light on the hormonal or immune-related underpinnings.
There's also an author correction published in Nature Communications on August 24th 2026, from Biao He at the Army Medical University in Chongqing China for a paper titled Host macrophages and monocytes promote malaria transmission by modulating mosquito microbiota via SR-A-mediated phagocytosis. Corrections are a normal and healthy part of the scientific process, and this one is worth knowing about given the significance of the original finding about how host immune cells can actually influence the microbiota of the mosquito vectors that transmit malaria.
In Gastroenterology from August 24th 2026, Astrid-Jane Williams from the IBD Centre of British Columbia in Vancouver and the University of New South Wales in Sydney asks Precision medicine in IBD are we there yet? Given everything we covered today about IBD pathophysiology and gut microbiome ecology, this timely clinical question is more relevant than ever.
And finally, Paul Hoskisson from the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde in Glasgow has a paper in PNAS for September 2026 titled Reshaping pathogen ecology in the Anthropocene. The Anthropocene is the current geological era defined by human impact on the planet, and this piece considers how human activities are fundamentally altering the ecology of pathogens, with profound implications for future infectious disease threats.
That's going to do it for this week's episode of KodaKoda's Weekly Immunology News. What a week. From IBD cell death mechanisms to carbon ion radiotherapy, from coral immune trade-offs to the mysteries of vaccine reactogenicity, immunology and microbiology are advancing on every front. Thank you so much for listening, and I'll see you next week with more cutting-edge science. Stay curious.